| 摘要 |
The peptides have unique effects on the immuno system, resulting in their efficacy in a wide range of syndromes including: viral infections, septic shock, autoimmune conditions, immune damage and/or disease progression in a patient suffering from one or more autoimmune condition, conditions associated with elevated Tumour Necrosis Factor (TNF), Interleukin 1 or 2 and/or Interferon. This can be achieved through the administration of therapeutic peptides disclosed herein, such as His-His-His-His-His-His-Glu-Ile-Cys-Pro-Ser-Phe-Gln-Arg-Val-Ile-Glu-Thr-Leu-Leu-Met-Asp-Thr-Pro-Ser-Ser-Tyr-Glu-Ala-Ala, or one or more other compound which binds to antibody to Clara Cell protein, or one or more other compound which comprises one or more amino acid sequence which is sufficiently homologous to Clara Cell protein (as defined herein) that the compound provides properties similar to those described herein for Clara Cell protein. There are also provided methods of implanting therapeutic peptides in patients, and articles for use in doing so. There are also provided pharmaceutical formulations of therapeutic peptides in sustained release forms. There are further provided pharmaceutical formulations for use in incorporating DNA in a patient's cells such that these cells can produce endogenous levels of therapeutic proteins as a prophylactic or therapeutic. |
